All In Biotech

Drug Trial Radar · NCT05716919

Multiple Ascending Dose Study of CG200745 'Ivaltinostat' Oral Capsule

A Phase I, Double Blind, Randomized, Placebo-controlled, Multiple Ascending Dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Orally Administered 'Ivaltinostat' Capsule in Healthy Male Volunteers

Last checked: Nov 20, 2026Latest source record: Oct 23, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

32

Actual

Start

Mar 9, 2023

Primary completion

Dec 2023

Study completion Dec 2023

Sponsor

Lead sponsor
Machaon Biotherapeutics, Inc.Industry
Sponsor type
Industry
First posted
Feb 8, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 19 years, up to 50 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

A Phase I, Double blind, Randomized, Placebo-controlled, Multiple Ascending Dose Study to evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Orally Administered 'CG-745' Capsule in Healthy Male Volunteers

Conditions

  • Hematologic Malignancy
  • Solid Tumor
  • Fibrosis

Interventions

  • IvaltinostatDrug

    Ivaltinostat capsule

  • PlaceboOther

    Placebo capsule

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Plasma Pharmacokinetic measures (Cmax, Cmax-ss)Time frame: up to 4 weeks
  2. Plasma Pharmacokinetic measures (AUC max, AUCmax-ss)Time frame: up to 4 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Seoul National University Hospital

    Seoul, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.